Comparing the current results to its competitors, Ngm Biopharmaceuticals Inc reported Revenue decrease in the 4 quarter 2023 year on year by -99.09 %, faster than the overall decrease of Ngm Biopharmaceuticals Inc 's competitors by -14.12 %, recorded in the same quarter.
Ngm Biopharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -39.39 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -39.39 %
Ngm Biopharmaceuticals Inc 's Comment on Competition and Industry Peers
The competitive landscape for primary sclerosing cholangitis (PSC) includes investigational drugs at various clinical stages. Dr. Falk Pharma leads with NorUDCA in Phase 3 trials in Europe. Additional programs in earlier stages are being developed by Hepagene Therapeutics, Inc., Cascade Pharmaceuticals, Inc., Orbsen Therapeutics Ltd., Chemomab Therapeutics Ltd., Curome Biosciences Co., Pliant Therapeutics, Inc., Escient Pharmaceuticals, Galmed Pharmaceuticals Ltd., GENFIT S.A., Mirum Pharmaceuticals, Inc., Ipsen S.A., and High Tide Therapeutics, Inc. The biopharmaceutical industry is competitive and rapidly evolving, with participants including multinational pharmaceutical companies, specialized biotechnology firms, universities, and research institutions. Notable pharmaceutical competitors include AbbVie, Amgen, AstraZeneca, Bayer, and Boehringer Ingelheim.
January 9, 2024
NGM Biopharmaceuticals, Inc. (NGM Bio), a prominent biotechnology company dedicated to revolutionizing therapeutic options for patients, recently shared promising clinical findings from an ongoing Phase 1 Part 1b study involving NGM707, a remarkable dual ILT2/ILT4 antagonist antibody candidate. Furthermore, NGM Bio presented its strategic plan to refocus the clinical development of aldafermin and NGM120 towards addressing rare conditions that are marked by substantial unmet medical requirements.The clinical data provided by NGM Bio showcases an encouraging outlook for NGM707. The ongoing study explores the efficacy and safety of NGM707 when administered in combination with KEYTRUDA (pembrolizumab), an establ...
Publicly Traded Peers of Ngm Biopharmaceuticals Inc
Biomarin Pharmaceutical Inc Share Performance
-1.26%
Over The Past 5 Days
Biomarin Pharmaceutical Inc
Profile
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
Acer Therapeutics Inc is a pharmaceutical company that operates on a business model focused on developing and commercializing innovative therapies for rare and severe diseases. They aim to identify unmet medical needs and provide treatment options for patients through strategic partnerships, clinical development, and commercialization efforts.
Cohbar Inc is a biotechnology company that focuses on the discovery and development of peptide-based therapeutics for the treatment of age-related diseases. Their business model revolves around leveraging their proprietary peptide technology platform and partnerships with pharmaceutical companies to advance and commercialize their drug candidates.
Forte Biosciences Inc is a biotechnology company focused on developing and commercializing innovative solutions for the treatment of dermatological diseases. Their business model centers around researching, developing, and bringing to market products that address unmet needs in the field of skin health through their proprietary technology platform.
Soligenix Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases. Their business model revolves around leveraging their expertise in developing innovative therapies and securing partnerships and collaborations with academic institutions, government agencies, and other companies to accelerate the development process. Soligenix also strategically seeks funding through grants and licensing deals to support their pipeline and growth initiatives.
Sources:
Ngm Biopharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ngm Biopharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
